Patents by Inventor David Bruce Baldwin

David Bruce Baldwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSION PROTEINS
    Publication number: 20220211818
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 7, 2022
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Fusion proteins and methods of use
    Patent number: 11253574
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: February 22, 2022
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • FUSION PROTEINS
    Publication number: 20200390865
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 17, 2020
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Fusion proteins
    Patent number: 10709766
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: July 14, 2020
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Blood glucose lowering compound
    Patent number: 10035839
    Abstract: The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound. The compound claimed herein comprises an A chain and a B chain, wherein the amino acid sequence of the A chain is SEQ ID NO: 1 and the amino acid sequence of the B chain is SEQ ID NO: 2.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: July 31, 2018
    Assignees: Eli Lilly and Company, Amunix Operating Inc.
    Inventors: David Bruce Baldwin, John Michael Beals, Andrew Ihor Korytko, Bryant Rhodius McLaughlin, Volker Schellenberger
  • FUSION PROTEINS
    Publication number: 20180177851
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 28, 2018
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Fusion proteins
    Patent number: 9855318
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: January 2, 2018
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • BLOOD GLUCOSE LOWERING COMPOUND
    Publication number: 20170240614
    Abstract: The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 24, 2017
    Inventors: David Bruce BALDWIN, John Michael BEALS, Andrew Ihor KORYTKO, Bryant Rhodius McLAUGHLIN, Volker SCHELLENBERGER
  • FUSION PROTEINS
    Publication number: 20160324932
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: April 28, 2016
    Publication date: November 10, 2016
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Soluble proteins that inhibit cytokine signal transduction pathways
    Publication number: 20040204351
    Abstract: This invention provides methods using secreted IL10-related cytokine receptor subunits, and variants and fusions and combinations thereof for treating and preventing, inflammatory system, immune system, and cardiovascular system disorders as well as hematopoiesis disorders and cancer.
    Type: Application
    Filed: March 23, 2004
    Publication date: October 14, 2004
    Inventors: Scott William Rowlinson, David Bruce Baldwin